MedinCell S.A.

Paris Stock Exchange MEDCL.PA

MedinCell S.A. Gross Profit Margin for the year ending March 31, 2024: 76.68%

MedinCell S.A. Gross Profit Margin is 76.68% for the year ending March 31, 2024, a -44.46% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

MedinCell S.A. Gross Profit Margin for the year ending March 31, 2023 was 138.08%, a -32.27% change year over year.
MedinCell S.A. Gross Profit Margin for the year ending March 31, 2022 was 203.86%, a 147.78% change year over year.
MedinCell S.A. Gross Profit Margin for the year ending March 31, 2021 was 82.27%, a 24.61% change year over year.
MedinCell S.A. Gross Profit Margin for the year ending March 31, 2020 was 66.02%, a 119.52% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Paris Stock Exchange: MEDCL.PA

MedinCell S.A.

CEO	Mr. Christophe Douat
IPO Date	Oct. 8, 2018
Location	France
Headquarters	3 rue des Frères Lumière
Employees	134
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Key trends

Past 5 years